ImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead Site
18 oct. 2022 08h00 HE
|
Immix Biopharma, Inc.
California Soft Tissue Sarcoma Site to lead expanded clinical site consortiumHistorically, high-enrolling lead site has enrolled 2-3 patients per monthClinical trial data expected to be released on a...
ImmixBio Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical Trials
07 sept. 2022 12h05 HE
|
Immix Biopharma, Inc.
Scaled-up, proprietary GMP manufacturing process to be utilized in 2 clinical trials:2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma (“STS”)2022 planned combination IMX-110 +...
ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study
20 mai 2022 08h47 HE
|
Immix Biopharma, Inc.
One cycle of IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug)In a connective tissue cancer Soft...
Immix Biopharma Announces Share Repurchase Program
09 mai 2022 08h00 HE
|
Immix Biopharma, Inc.
LOS ANGELES, May 09, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM...
ImmixBio Management Discusses Key Milestones, Drug Development Timelines and the IMMX Advantage at IMMX Milestone Day Event Held on April 5, 2022
05 avr. 2022 09h30 HE
|
Immix Biopharma, Inc.
The IMMX Milestone Day Event is viewable at www.immixbio.com/Apr2022MilestoneDayManagement discussed financial position, milestones, and new opportunities presented by current market...
Immix Biopharma, Inc. Announces IMMX Milestone Day to be Held on April 5, 2022
07 mars 2022 08h00 HE
|
Immix Biopharma, Inc.
Management plans to discuss current financial position, milestones, and new opportunities presented by current market volatilityWith $24.2 million gross proceeds from its December 2021 IPO, ImmixBio...
ImmixBio Initiates GMP Manufacturing of IMX-120, a Biologic for Inflammatory Bowel Disease
22 févr. 2022 08h00 HE
|
Immix Biopharma, Inc.
IMX-120 utilizes proprietary, humanized antibody fragment to selectively silence disease-causing, overactive inflammatory bowel immune cellsImmixBio anticipates filing an IND for IMX-120 in 2023The...
ImmixBio Management Answers Top-Voted Investor Questions at IMMX Investors Day February 1, 2022
01 févr. 2022 09h30 HE
|
Immix Biopharma, Inc.
LOS ANGELES, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics...
ImmixBio Initiates IMX-110 GMP Manufacturing Scale-Up, Potentially Accelerating Clinical Trial Data
31 janv. 2022 08h00 HE
|
Immix Biopharma, Inc.
Manufactured IMX-110 to be utilized in both clinical trials:2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma (“STS”)2022 planned combination IMX-110 + BeiGene anti-PD-1...
IMX-110 + anti-PD-1 Combination Produced Extended Median Survival in Genetic Pancreatic Cancer Mouse Model, Bolstering Planned 2022 IMX-110 Combination Clinical Trial Rationale
25 janv. 2022 10h15 HE
|
Immix Biopharma, Inc.
IMX-110 + anti-PD-1 produced 63-day median survival in a genetic (KPC) pancreatic cancer mouse model in which mice develop their own pancreatic cancer and have an intact immune systemHistorically,...